Mirum Pharmaceuticals Inc. is a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions. The company's lead product candidate, maralixibat, is a Phase 3-ready investigational oral drug with an established safety profile and efficacy data in several indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/07/18 | $120,000,000 | Series A |
Deerfield Management Company, L.P. Frazier Healthcare New Enterprise Associates  Novo Pappas Capital RiverVest Venture Partners Rock Springs Capital | undisclosed |
